US regulatory status: approved.
pharma · Hepatocellular Carcinoma · Obesity
Hospital Authority
Hospital Authority, Hong Kong
Hospital Authority drug portfolio — 200 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Hospital Authority Building, 147B Argyle Street, Kowloon, Hong Kong, 852, HK, CN HQ
1991 Founded
12,669 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Hospital Authority Building, 147B Argyle Street, Kowloon, Hong Kong, 852, HK, CN
- Founded
- 1991
- Employees
- 12,669
- Programs
- 322
- Drugs
- 301
- Patents
- 0
Hospital Authority pipeline
Portfolio lens on 200 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Hospital Authority drug portfolio — 200 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Synaptosomal-associated protein 25.
- Target
- Synaptosomal-associated protein 25
- Mechanism
- Synaptosomal-associated protein 25 inhibitor
-
US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Cyclooxygenase inhibitor
-
US regulatory status: approved. Mechanism: Glutathione precursor.
- Mechanism
- Glutathione precursor
-
US regulatory status: approved. Molecular target: DNA polymerase catalytic subunit.
- Target
- DNA polymerase catalytic subunit
- Mechanism
- Human herpesvirus 1 DNA polymerase inhibitor
-
adefovir dipivoxil
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: DNA polymerase/reverse transcriptase.
- Target
- DNA polymerase/reverse transcriptase
- Mechanism
- DNA polymerase/reverse transcriptase inhibitor
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
Development asset linked to Hospital Authority in public FDA and regional records. Molecular target: Adrenergic receptor.
- Target
- Adrenergic receptor
- Mechanism
- Adrenergic receptor agonist
-
US regulatory status: approved.
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Farnesyl pyrophosphate synthase.
- Target
- Farnesyl pyrophosphate synthase
- Mechanism
- Farnesyl diphosphate synthase inhibitor
-
allogeneic umbilical cord-derived cd34- cells, non-expanded
Blood and blood forming organs (B05)Blood and blood forming organs (B05) compound in Hospital Authority's portfolio.
-
allopurinol
Musculo-skeletal system (M04)US regulatory status: approved. Molecular target: Xanthine dehydrogenase/oxidase.
- Target
- Xanthine dehydrogenase/oxidase
- Mechanism
- Xanthine dehydrogenase inhibitor
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Phosphodiesterase 4.
- Target
- Phosphodiesterase 4
- Mechanism
- Phosphodiesterase 4 inhibitor
-
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
aripiprazole
Nervous system (N05)US regulatory status: approved. Molecular target: D(2) dopamine receptor.
- Target
- D(2) dopamine receptor
- Mechanism
- Serotonin 2a (5-HT2a) receptor antagonist
-
artesunate
Antiparasitic products (P01)US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
US regulatory status: approved. Molecular target: D(2) dopamine receptor.
- Target
- D(2) dopamine receptor
- Mechanism
- Dopamine D2 receptor antagonist
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
Development asset linked to Hospital Authority in public FDA and regional records. Mechanism: HMG-CoA reductase inhibitor.
- Mechanism
- HMG-CoA reductase inhibitor
-
atosiban
Genito-urinary system and sex hormones (G02)Genito-urinary system and sex hormones (G02) compound in Hospital Authority's portfolio. Molecular target: Oxytocin receptor.
- Target
- Oxytocin receptor
- Mechanism
- Oxytocin receptor antagonist
-
atropine sulfate
Sensory organs (S01)US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M3 antagonist
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
avatrombopag
Blood and blood forming organs (B02)Blood and blood forming organs (B02) compound in Hospital Authority's portfolio. Molecular target: Thrombopoietin receptor.
- Target
- Thrombopoietin receptor
- Mechanism
- Thrombopoietin receptor agonist
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
bevacizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.
- Target
- Vascular endothelial growth factor A, long form
- Mechanism
- Vascular endothelial growth factor A inhibitor
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
bortezomib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: 26S proteasome.
- Target
- 26S proteasome
- Mechanism
- 26S proteosome inhibitor
-
botulinum toxin type a
Musculo-skeletal system (M03)Musculo-skeletal system (M03) compound in Hospital Authority's portfolio. Molecular target: Synaptosomal-associated protein 25.
- Target
- Synaptosomal-associated protein 25
- Mechanism
- Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
brentuximab vedotin
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
US regulatory status: approved. Mechanism: Membrane staining aid in ophthalmic surgery.
- Mechanism
- Membrane staining aid in ophthalmic surgery
-
bupivacaine
Nervous system (N01)US regulatory status: approved. Molecular target: Sodium channel protein type 4 subunit alpha.
- Target
- Sodium channel protein type 4 subunit alpha
- Mechanism
- Sodium channel protein type IV alpha subunit blocker
-
US regulatory status: approved. Molecular target: Sodium channel protein type 4 subunit alpha.
- Target
- Sodium channel protein type 4 subunit alpha
- Mechanism
- Sodium channel protein type IV alpha subunit blocker
-
US regulatory status: approved. Molecular target: Vitamin D3 receptor.
- Target
- Vitamin D3 receptor
- Mechanism
- Vitamin D receptor agonist
-
US regulatory status: approved.
-
US regulatory status: approved.
-
US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.
- Mechanism
- Dihydrofolate reductase inhibitor
-
cannabidiol
Nervous system (N03)US regulatory status: approved. Molecular target: Cannabinoid receptor 1.
- Target
- Cannabinoid receptor 1
- Mechanism
- Cannabinoid CB1 receptor negative allosteric modulator
-
capecitabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Thymidylate synthase inhibitor
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
celecoxib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Prostaglandin G/H synthase 2.
- Target
- Prostaglandin G/H synthase 2
- Mechanism
- Cyclooxygenase-2 inhibitor
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
-
cetuximab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins
Musculo-skeletal system (M09)Musculo-skeletal system (M09) compound in Hospital Authority's portfolio. Mechanism: Somatic cell supplemental therapy.
- Mechanism
- Somatic cell supplemental therapy
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Cell membrane.
- Target
- Cell membrane
- Mechanism
- Cell membrane inhibitor
-
cholic acid
Alimentary tract and metabolism (A05)US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
US regulatory status: approved. Molecular target: cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A.
- Target
- cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A
- Mechanism
- Phosphodiesterase 3A inhibitor
-
cinacalcet
Systemic hormonal preparations (H05)Systemic hormonal preparations (H05) compound in Hospital Authority's portfolio. Mechanism: Calcium sensing receptor positive allosteric modulator.
- Mechanism
- Calcium sensing receptor positive allosteric modulator
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Molecular target: Adrenergic receptor alpha-2.
- Target
- Adrenergic receptor alpha-2
- Mechanism
- Adrenergic receptor alpha-2 agonist
-
clopidogrel
Blood and blood forming organs (B01)Blood and blood forming organs (B01) compound in Hospital Authority's portfolio. Mechanism: Purinergic receptor P2Y12 antagonist.
- Mechanism
- Purinergic receptor P2Y12 antagonist
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
Development asset linked to Hospital Authority in public FDA and regional records. Molecular target: Placenta growth factor.
- Target
- Placenta growth factor
- Mechanism
- Vascular endothelial growth factor A inhibitor
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
covid-19 vaccine (inactivated, adjuvanted, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Hospital Authority's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
cytarabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
dapagliflozin
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Sodium/glucose cotransporter 2.
- Target
- Sodium/glucose cotransporter 2
- Mechanism
- Sodium/glucose cotransporter 2 inhibitor
-
daptomycin
Antiinfectives for systemic use (J01)US regulatory status: approved. Molecular target: Cell membrane.
- Target
- Cell membrane
- Mechanism
- Cell membrane inhibitor
-
daunorubicin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Hospital Authority's portfolio. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
decitabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA (cytosine-5)-methyltransferase 1.
- Target
- DNA (cytosine-5)-methyltransferase 1
- Mechanism
- DNA (cytosine-5)-methyltransferase 1 inhibitor
-
dengue tetravalent vaccine (live, attenuated)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Hospital Authority's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
US regulatory status: approved. Molecular target: Cell membrane.
- Target
- Cell membrane
- Mechanism
- Cell membrane disrupting agent
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
dexmedetomidine
Nervous system (N05)Nervous system (N05) compound in Hospital Authority's portfolio. Mechanism: Adrenergic receptor alpha-2 agonist.
- Mechanism
- Adrenergic receptor alpha-2 agonist
-
US regulatory status: approved.
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
US regulatory status: approved. Molecular target: Sodium/potassium-transporting ATPase.
- Target
- Sodium/potassium-transporting ATPase
- Mechanism
- Sodium/potassium-transporting ATPase inhibitor
-
diphtheria (d), tetanus (t), pertussis (acellular, component) (pa), hepatitis b (rdna) (hbv), poliomyelitis (inactivated) (ipv) and haemophilus influenzae type-b (hib) conjugate vaccine (adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Hospital Authority's portfolio.
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
docetaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
dostarlimab
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Hospital Authority's portfolio. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 antagonist
-
US regulatory status: approved. Molecular target: Adrenergic receptor alpha-1.
- Target
- Adrenergic receptor alpha-1
- Mechanism
- Adrenergic receptor alpha-1 antagonist
-
doxorubicin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Hospital Authority's portfolio. Mechanism: DNA topoisomerase II alpha inhibitor.
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Matrix metalloproteinase 8 inhibitor
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Matrix metalloproteinase-1 inhibitor
-
dupilumab
Dermatologicals (D11)US regulatory status: approved. Molecular target: Interleukin-4 receptor subunit alpha.
- Target
- Interleukin-4 receptor subunit alpha
- Mechanism
- Interleukin-4 receptor subunit alpha antagonist
-
durvalumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
- Target
- Programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 inhibitor
-
US regulatory status: approved. Molecular target: Progesterone receptor.
- Target
- Progesterone receptor
- Mechanism
- Progesterone receptor agonist
-
empagliflozin
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Sodium/glucose cotransporter 2.
- Target
- Sodium/glucose cotransporter 2
- Mechanism
- Sodium/glucose cotransporter 2 inhibitor
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
entecavir
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: DNA polymerase/reverse transcriptase.
- Target
- DNA polymerase/reverse transcriptase
- Mechanism
- DNA polymerase/reverse transcriptase inhibitor
-
epinephrine
Cardiovascular system (C01)US regulatory status: approved. Molecular target: Adrenergic receptor.
- Target
- Adrenergic receptor
- Mechanism
- Adrenergic receptor agonist
-
US regulatory status: approved. Molecular target: Adrenergic receptor.
- Target
- Adrenergic receptor
- Mechanism
- Adrenergic receptor agonist
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Vitamin D3 receptor.
- Target
- Vitamin D3 receptor
- Mechanism
- Vitamin D receptor agonist
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive modulator
-
fentanyl
Nervous system (N02)US regulatory status: approved. Molecular target: Mu-type opioid receptor.
- Target
- Mu-type opioid receptor
- Mechanism
- Mu opioid receptor agonist
-
US regulatory status: approved. Molecular target: Mu-type opioid receptor.
- Target
- Mu-type opioid receptor
- Mechanism
- Mu opioid receptor agonist
-
US regulatory status: approved. Mechanism: Supplement.
- Mechanism
- Supplement
-
US regulatory status: approved.
-
US regulatory status: approved. Mechanism: Supplement.
- Mechanism
- Supplement
-
filgrastim
Antineoplastic and immunomodulating agents (L03)US regulatory status: approved. Molecular target: Granulocyte colony-stimulating factor receptor.
- Target
- Granulocyte colony-stimulating factor receptor
- Mechanism
- Granulocyte colony stimulating factor receptor agonist
-
finerenone
Cardiovascular system (C09)US regulatory status: approved. Molecular target: Mineralocorticoid receptor.
- Target
- Mineralocorticoid receptor
- Mechanism
- Mineralocorticoid receptor antagonist
-
florbetaben (18f)
Various (V09)Various (V09) compound in Hospital Authority's portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Thymidylate synthase inhibitor
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
folic acid
Various (V04)US regulatory status: approved.
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Voltage-gated calcium channel.
- Target
- Voltage-gated calcium channel
- Mechanism
- Voltage-gated calcium channel modulator
-
US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
US regulatory status: approved. Molecular target: Peroxisome proliferator-activated receptor alpha.
- Target
- Peroxisome proliferator-activated receptor alpha
- Mechanism
- Peroxisome proliferator-activated receptor alpha agonist
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Enoyl-[acyl-carrier-protein] reductase [NADH] FabI.
- Target
- Enoyl-[acyl-carrier-protein] reductase [NADH] FabI
- Mechanism
- Bacterial enoyl-[acyl-carrier-protein] reductase inhibitor
-
US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M1 antagonist
-
Development asset linked to Hospital Authority in public FDA and regional records. Mechanism: Protein synthesis inhibitor.
- Mechanism
- Protein synthesis inhibitor
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
Development asset linked to Hospital Authority in public FDA and regional records. Molecular target: Focal adhesion kinase 1.
- Target
- Focal adhesion kinase 1
- Mechanism
- Focal adhesion kinase 1 inhibitor
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
influenza vaccine (live attenuated, nasal)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Hospital Authority's portfolio.
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
Development asset linked to Hospital Authority in public FDA and regional records. Molecular target: Insulin receptor.
- Target
- Insulin receptor
- Mechanism
- Insulin receptor agonist
-
interferon alfa-2a
Antineoplastic and immunomodulating agents (L03)Antineoplastic and immunomodulating agents (L03) compound in Hospital Authority's portfolio. Molecular target: Interferon alpha/beta receptor.
- Target
- Interferon alpha/beta receptor
- Mechanism
- Interferon alpha/beta receptor agonist
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Supplement.
- Mechanism
- Supplement
-
US regulatory status: approved. Molecular target: Enoyl-[acyl-carrier-protein] reductase [NADH].
- Target
- Enoyl-[acyl-carrier-protein] reductase [NADH]
- Mechanism
- Enoyl-[acyl-carrier-protein] reductase inhibitor
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
ixekizumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Interleukin-17A.
- Target
- Interleukin-17A
- Mechanism
- Interleukin 17A inhibitor
-
Development asset linked to Hospital Authority in public FDA and regional records. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 antagonist
-
ketoconazole
Antiinfectives for systemic use (J02)US regulatory status: approved. Molecular target: Lanosterol 14-alpha demethylase.
- Target
- Lanosterol 14-alpha demethylase
- Mechanism
- Cytochrome P450 51 inhibitor
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
lapatinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Hospital Authority's portfolio. Mechanism: Receptor protein-tyrosine kinase erbB-2 inhibitor.
- Mechanism
- Receptor protein-tyrosine kinase erbB-2 inhibitor
-
larotrectinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Hospital Authority's portfolio. Molecular target: Neurotrophic tyrosine kinase receptor.
- Target
- Neurotrophic tyrosine kinase receptor
- Mechanism
- Neurotrophic tyrosine kinase receptor inhibitor
-
lenalidomide
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: CRL4(CRBN) E3 ubiquitin ligase.
- Target
- CRL4(CRBN) E3 ubiquitin ligase
- Mechanism
- CRL4(CRBN) E3 ubiquitin ligase inhibitor
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
levofloxacin
Antiinfectives for systemic use (J01)US regulatory status: approved. Molecular target: DNA gyrase.
- Target
- DNA gyrase
- Mechanism
- DNA gyrase inhibitor
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
Development asset linked to Hospital Authority in public FDA and regional records. Mechanism: Mitochondrial complex I (NADH dehydrogenase) inhibitor.
- Mechanism
- Mitochondrial complex I (NADH dehydrogenase) inhibitor
-
methotrexate
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Dihydrofolate reductase inhibitor
-
US regulatory status: approved. Mechanism: Reducing agent.
- Mechanism
- Reducing agent
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
midazolam
Nervous system (N05)US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive allosteric modulator
-
mifepristone
Nervous system (NOT)US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Progesterone receptor antagonist
-
US regulatory status: approved. Molecular target: Sulfonylurea receptor 2, Kir6.2.
- Target
- Sulfonylurea receptor 2, Kir6.2
- Mechanism
- Sulfonylurea receptor 2, Kir6.2 opener
-
mirabegron
Genito-urinary system and sex hormones (G04)US regulatory status: approved. Molecular target: Beta-3 adrenergic receptor.
- Target
- Beta-3 adrenergic receptor
- Mechanism
- Beta-3 adrenergic receptor agonist
-
Development asset linked to Hospital Authority in public FDA and regional records. Mechanism: Mu opioid receptor agonist.
- Mechanism
- Mu opioid receptor agonist
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
Development asset linked to Hospital Authority in public FDA and regional records. Molecular target: Nischarin.
- Target
- Nischarin
- Mechanism
- Nischarin agonist
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Isoleucine--tRNA ligase.
- Target
- Isoleucine--tRNA ligase
- Mechanism
- Isoleucyl-tRNA synthetase inhibitor
-
US regulatory status: approved. Molecular target: Isoleucine--tRNA ligase.
- Target
- Isoleucine--tRNA ligase
- Mechanism
- Isoleucyl-tRNA synthetase inhibitor
-
Various (V04) compound in Hospital Authority's portfolio.
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Opioid receptors; mu/kappa/delta.
- Target
- Opioid receptors; mu/kappa/delta
- Mechanism
- Opioid receptors; mu/kappa/delta antagonist
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
Development asset linked to Hospital Authority in public FDA and regional records.
-
nitric oxide
Respiratory system (R07)US regulatory status: approved. Molecular target: Soluble guanylate cyclase.
- Target
- Soluble guanylate cyclase
- Mechanism
- Soluble guanylate cyclase activator
-
US regulatory status: approved. Molecular target: Bacterial DNA gyrase.
- Target
- Bacterial DNA gyrase
- Mechanism
- Bacterial DNA gyrase inhibitor
-
olaparib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: PARP 1, 2 and 3.
- Target
- PARP 1, 2 and 3
- Mechanism
- PARP 1, 2 and 3 inhibitor